stockportfolio.pro
Novartis AG (NVS)
Healthcare · Drug Manufacturers - General · NYSE
Novartis AG revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $43.46B | $46.66B | $51.72B | $56.67B |
| Gross profit | $31.88B | $34.19B | $38.90B | $42.98B |
| Net income | $6.96B | $14.85B | $11.94B | $13.98B |
| Net margin | 16.0% | 31.8% | 23.1% | 24.7% |
Source: Novartis AG SEC filings (10-K).
What growth is priced into NVS stock?
At today's market cap of $290.63B, Novartis AG is priced for free-cash-flow growth of about 7.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $15.24B from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of Novartis AG financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NVS in your portfolio →
Novartis AG financial history by metric
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG — frequently asked questions
What is Novartis AG's revenue?
Novartis AG (NVS) reported revenue of $56.67B for fiscal year 2025, up 9.6% from the prior year, according to its SEC filings.
Is Novartis AG profitable?
Yes. NVS earned net income of $13.98B in fiscal 2025, a net margin of 24.7%.
What is NVS's P/E ratio?
Novartis AG trades at a price-to-earnings ratio of about 21.8 based on the latest data in our nightly-refreshed cache.
How fast is Novartis AG growing?
NVS's revenue grew at roughly 9.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Novartis AG have?
As of fiscal year 2025, NVS carried roughly $33.46B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Novartis AG's gross margin?
NVS's gross margin was 75.8% in fiscal 2025 — gross profit of $42.98B on revenue of $56.67B.
What is Novartis AG's market cap?
Novartis AG (NVS) has a market capitalization of about $290.63B, based on the latest data in our nightly-refreshed cache.
When does Novartis AG's fiscal year end?
NVS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into NVS stock?
At today's market cap of $290.63B, Novartis AG is priced for free-cash-flow growth of about 7.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $15.24B from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Novartis AG's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.